Baxter's Latest Hemophilia Drug Comes Through in Phase III

Friday, March 13, 2015

Source: Fierce Biotech

Baxter ($BAX), on the eve of biotech spinout, declared Phase III victory for a hemophilia treatment designed to help patients not responding to standard therapy.

The drug, BAX 817, is designed to replace the missing blood factors that stop blood from clotting normally and cause hemophilia. Many hemophilia patients come to develop inhibitors of such factor-replacement therapies, and Baxter's latest treatment is designed with them in mind.

In an open-label Phase III study on hemophilia A or B patients with inhibitors, BAX 817 met its primary endpoint of treating acute bleeding episodes after 12 hours of administration, the company said. The injected drug notched an overall success rate of 92% after 12 hours, according to Baxter, and 89% of patients reported sustained bleeding control after 24 hours. And, importantly, the drug didn't spur the development of any new inhibitors or binding antibodies, Baxter said.

View All News »